幼年和成年特发性炎症性肌病的自身抗体表型和长期疗效的差异

IF 4.6 2区 医学 Q1 RHEUMATOLOGY Seminars in arthritis and rheumatism Pub Date : 2024-08-08 DOI:10.1016/j.semarthrit.2024.152530
Hideaki Tsuji , Ran Nakashima , Takahiro Yasumi , Tsuneo Sasai , Yuki Ichimura , Mirei Shirakashi , Hideo Onizawa , Ryosuke Hiwa , Koji Kitagori , Shuji Akizuki , Akira Onishi , Hajime Yoshifuji , Masao Tanaka , Naoko Okiyama , Tsuneyo Mimori , Akio Morinobu
{"title":"幼年和成年特发性炎症性肌病的自身抗体表型和长期疗效的差异","authors":"Hideaki Tsuji ,&nbsp;Ran Nakashima ,&nbsp;Takahiro Yasumi ,&nbsp;Tsuneo Sasai ,&nbsp;Yuki Ichimura ,&nbsp;Mirei Shirakashi ,&nbsp;Hideo Onizawa ,&nbsp;Ryosuke Hiwa ,&nbsp;Koji Kitagori ,&nbsp;Shuji Akizuki ,&nbsp;Akira Onishi ,&nbsp;Hajime Yoshifuji ,&nbsp;Masao Tanaka ,&nbsp;Naoko Okiyama ,&nbsp;Tsuneyo Mimori ,&nbsp;Akio Morinobu","doi":"10.1016/j.semarthrit.2024.152530","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>To investigate differences in autoantibodies, clinical features, and long-term outcomes between juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM</p></div><div><h3>Methods</h3><p>Autoantibodies, clinical characteristics, and drug-free conditions for a maximum of 20 years were retrospectively analyzed in 320 Japanese IIM patients (juvenile-IIM, <em>n</em> = 34; adult-IIM, <em>n</em> = 286) using the Kyoto University Registry.</p></div><div><h3>Results</h3><p>Autoantibodies observed in juvenile-IIM were anti-TIF1-γ (15 %), anti-MDA-5 (15 %), anti-ARS (9 %), and anti-NXP-2 (6 %). Those observed in adult-IIM were anti-ARS (32 %), anti-MDA-5 (23 %), anti-TIF1-γ (8 %), anti-SRP (8 %), anti-Mi-2 (2 %), and anti-NXP-2 (1 %). The cumulative drug-free condition rate was higher in juvenile-IIM than in adult-IIM up to 20 years (juvenile-IIM vs. adult-IIM, 34 % vs. 18 %, <em>p</em> = 0.0016). Anti-TIF1-γ was associated with lesser muscle symptoms (60 % vs. 90 %), malignancy (0 % vs. 57 %), and glucocorticoid use (40 % vs. 86 %) in juvenile-IIM compared to adult-IIM, while juvenile-IIM more achieved drug-free conditions (60 % vs. 25 %). Both juvenile-IIM and adult-IIM with anti-MDA-5 demonstrated a high frequency of amyopathic dermatomyositis, interstitial lung disease (ILD), and multi-immunosuppressive therapy, with high drug-free conditions (50 % vs. 49 %). Both juvenile-IIM and adult-IIM with anti-ARS showed frequent skin rashes, muscle symptoms, and ILD, frequent need for multi-immunosuppressive therapy, and low drug-free condition rates (0 % vs. 3 %). Both juvenile-IIM and adult-IIM with anti-NXP-2 showed frequent skin rashes and muscle symptoms, low ILD frequency, and frequent use of methotrexate and glucocorticoids, which did not achieve drug-free conditions (0 % vs. 0 %).</p></div><div><h3>Conclusions</h3><p>Drug-free condition was achieved more frequently in juvenile-IIM patients than adult-IIM patients. Specific autoantibodies were associated with different clinical characteristics and outcomes between juvenile-IIM and adult-IIM.</p></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Differences in the autoantibody phenotypes and long-term outcomes between juvenile- and adult-idiopathic inflammatory myopathies\",\"authors\":\"Hideaki Tsuji ,&nbsp;Ran Nakashima ,&nbsp;Takahiro Yasumi ,&nbsp;Tsuneo Sasai ,&nbsp;Yuki Ichimura ,&nbsp;Mirei Shirakashi ,&nbsp;Hideo Onizawa ,&nbsp;Ryosuke Hiwa ,&nbsp;Koji Kitagori ,&nbsp;Shuji Akizuki ,&nbsp;Akira Onishi ,&nbsp;Hajime Yoshifuji ,&nbsp;Masao Tanaka ,&nbsp;Naoko Okiyama ,&nbsp;Tsuneyo Mimori ,&nbsp;Akio Morinobu\",\"doi\":\"10.1016/j.semarthrit.2024.152530\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>To investigate differences in autoantibodies, clinical features, and long-term outcomes between juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM</p></div><div><h3>Methods</h3><p>Autoantibodies, clinical characteristics, and drug-free conditions for a maximum of 20 years were retrospectively analyzed in 320 Japanese IIM patients (juvenile-IIM, <em>n</em> = 34; adult-IIM, <em>n</em> = 286) using the Kyoto University Registry.</p></div><div><h3>Results</h3><p>Autoantibodies observed in juvenile-IIM were anti-TIF1-γ (15 %), anti-MDA-5 (15 %), anti-ARS (9 %), and anti-NXP-2 (6 %). Those observed in adult-IIM were anti-ARS (32 %), anti-MDA-5 (23 %), anti-TIF1-γ (8 %), anti-SRP (8 %), anti-Mi-2 (2 %), and anti-NXP-2 (1 %). The cumulative drug-free condition rate was higher in juvenile-IIM than in adult-IIM up to 20 years (juvenile-IIM vs. adult-IIM, 34 % vs. 18 %, <em>p</em> = 0.0016). Anti-TIF1-γ was associated with lesser muscle symptoms (60 % vs. 90 %), malignancy (0 % vs. 57 %), and glucocorticoid use (40 % vs. 86 %) in juvenile-IIM compared to adult-IIM, while juvenile-IIM more achieved drug-free conditions (60 % vs. 25 %). Both juvenile-IIM and adult-IIM with anti-MDA-5 demonstrated a high frequency of amyopathic dermatomyositis, interstitial lung disease (ILD), and multi-immunosuppressive therapy, with high drug-free conditions (50 % vs. 49 %). Both juvenile-IIM and adult-IIM with anti-ARS showed frequent skin rashes, muscle symptoms, and ILD, frequent need for multi-immunosuppressive therapy, and low drug-free condition rates (0 % vs. 3 %). Both juvenile-IIM and adult-IIM with anti-NXP-2 showed frequent skin rashes and muscle symptoms, low ILD frequency, and frequent use of methotrexate and glucocorticoids, which did not achieve drug-free conditions (0 % vs. 0 %).</p></div><div><h3>Conclusions</h3><p>Drug-free condition was achieved more frequently in juvenile-IIM patients than adult-IIM patients. Specific autoantibodies were associated with different clinical characteristics and outcomes between juvenile-IIM and adult-IIM.</p></div>\",\"PeriodicalId\":21715,\"journal\":{\"name\":\"Seminars in arthritis and rheumatism\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2024-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in arthritis and rheumatism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0049017224001707\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in arthritis and rheumatism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0049017224001707","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的 研究幼年型特发性炎症性肌病(IIM)和成年型特发性炎症性肌病之间在自身抗体、临床特征和长期预后方面的差异。方法 使用京都大学登记表对 320 名日本 IIM 患者(幼年型 IIIM,34 人;成年型 IIIM,286 人)的自身抗体、临床特征和最长 20 年的无药状态进行了回顾性分析。结果 在青少年 IIIM 中观察到的自身抗体有抗 TIF1-γ (15%)、抗 MDA-5 (15%)、抗ARS (9%)和抗 NXP-2 (6%)。在成人-IIM 中观察到的抗ARS(32%)、抗 MDA-5(23%)、抗 TIF1-γ(8%)、抗 SRP(8%)、抗 Mi-2(2%)和抗 NXP-2(1%)。20 年内,青少年 IIM 的累积无药状态率高于成年 IIM(青少年 IIM 与成年 IIM 相比,34 % 对 18 %,p = 0.0016)。与成年 IIM 相比,抗 TIF1-γ 与青少年 IIM 较少的肌肉症状(60% 对 90%)、恶性肿瘤(0% 对 57%)和糖皮质激素的使用(40% 对 86%)有关,而青少年 IIM 则更多地达到了无药状态(60% 对 25%)。患有抗 MDA-5 的幼年 IIM 和成年 IIM 均表现出较高的肌病性皮肌炎、间质性肺病(ILD)和多重免疫抑制治疗的频率,无药物治疗的比例较高(50% 对 49%)。患有抗ARS的幼年 IIM 和成年 IIM 都经常出现皮疹、肌肉症状和 ILD,经常需要接受多种免疫抑制治疗,无药状态率低(0% 对 3%)。抗 NXP-2 的幼年 IIM 和成年 IIM 均频繁出现皮疹和肌肉症状,ILD 发生率低,频繁使用甲氨蝶呤和糖皮质激素,但均未达到无药状态(0 % vs. 0 %)。特异性自身抗体与幼年胰岛素瘤和成年胰岛素瘤的不同临床特征和预后有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Differences in the autoantibody phenotypes and long-term outcomes between juvenile- and adult-idiopathic inflammatory myopathies

Objective

To investigate differences in autoantibodies, clinical features, and long-term outcomes between juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM

Methods

Autoantibodies, clinical characteristics, and drug-free conditions for a maximum of 20 years were retrospectively analyzed in 320 Japanese IIM patients (juvenile-IIM, n = 34; adult-IIM, n = 286) using the Kyoto University Registry.

Results

Autoantibodies observed in juvenile-IIM were anti-TIF1-γ (15 %), anti-MDA-5 (15 %), anti-ARS (9 %), and anti-NXP-2 (6 %). Those observed in adult-IIM were anti-ARS (32 %), anti-MDA-5 (23 %), anti-TIF1-γ (8 %), anti-SRP (8 %), anti-Mi-2 (2 %), and anti-NXP-2 (1 %). The cumulative drug-free condition rate was higher in juvenile-IIM than in adult-IIM up to 20 years (juvenile-IIM vs. adult-IIM, 34 % vs. 18 %, p = 0.0016). Anti-TIF1-γ was associated with lesser muscle symptoms (60 % vs. 90 %), malignancy (0 % vs. 57 %), and glucocorticoid use (40 % vs. 86 %) in juvenile-IIM compared to adult-IIM, while juvenile-IIM more achieved drug-free conditions (60 % vs. 25 %). Both juvenile-IIM and adult-IIM with anti-MDA-5 demonstrated a high frequency of amyopathic dermatomyositis, interstitial lung disease (ILD), and multi-immunosuppressive therapy, with high drug-free conditions (50 % vs. 49 %). Both juvenile-IIM and adult-IIM with anti-ARS showed frequent skin rashes, muscle symptoms, and ILD, frequent need for multi-immunosuppressive therapy, and low drug-free condition rates (0 % vs. 3 %). Both juvenile-IIM and adult-IIM with anti-NXP-2 showed frequent skin rashes and muscle symptoms, low ILD frequency, and frequent use of methotrexate and glucocorticoids, which did not achieve drug-free conditions (0 % vs. 0 %).

Conclusions

Drug-free condition was achieved more frequently in juvenile-IIM patients than adult-IIM patients. Specific autoantibodies were associated with different clinical characteristics and outcomes between juvenile-IIM and adult-IIM.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
9.20
自引率
4.00%
发文量
176
审稿时长
46 days
期刊介绍: Seminars in Arthritis and Rheumatism provides access to the highest-quality clinical, therapeutic and translational research about arthritis, rheumatology and musculoskeletal disorders that affect the joints and connective tissue. Each bimonthly issue includes articles giving you the latest diagnostic criteria, consensus statements, systematic reviews and meta-analyses as well as clinical and translational research studies. Read this journal for the latest groundbreaking research and to gain insights from scientists and clinicians on the management and treatment of musculoskeletal and autoimmune rheumatologic diseases. The journal is of interest to rheumatologists, orthopedic surgeons, internal medicine physicians, immunologists and specialists in bone and mineral metabolism.
期刊最新文献
Real-world assessment of the efficacy and tolerability profile of JAK inhibitors in difficult-to-treat rheumatoid arthritis Systematic review of treatments for the gastrointestinal manifestations of systemic lupus erythematosus Primary headache in SLE –systematic review and meta-analysis Information and communication technology-based patient education for autoimmune inflammatory rheumatic diseases: A scoping review Improvement in spinal pain at night and its impact on long-term outcomes in radiographic axial spondyloarthritis: Results from Ixekizumab COAST-V randomised trial
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1